Figures & data
Table 1. Uncontrolled echocardiographic studies.
Table 2: Echocardiographic findings in controlled clinical studies of fenfluramine and related drugs in adult patients treated for obesity
Table 3. Echocardiographic findings in the two Belgian cohorts of patients with Dravet syndrome treated with fenfluramine.
Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001;79:159-65 Bowen R, Glicklich A, Khan M, et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6 Fisher EA, Ruden R. Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. Cardiovasc Rev Rep 1998;19:13-16 Kancherla MK, Salti HI, Mulderink TA, et al. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999;84:1335-8 Lepor NE, Gross SB, Daley WL, et al. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000;86:107-10 Teramae CY, Connolly HM, Grogan M, et al. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000;75:456-61 Wadden TA, Berkowitz RI, Silvestry F, et al. The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998;6:278-84 Dahl CF, Allen MR, Urie PM, et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34 Loke YK, Derry S, Pritchard-Copley A. Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2002;2:6 Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-9 Hensrud DD, Connolly HM, Grogan M, et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-7 Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7 Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-18 Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-7 Wee CC, Phillips RS, Aurigemma G, et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998;129:870-4 Weissman NJ, Tighe JF Jr, Gottdiener JS, et al. Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32 Davidoff R, McTiernan A, Constantine G, et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429-36 Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313-22 Schoonjans A-S, Marchau F, Paelinck B, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: update of the prospective study. Presented at the 70th Annual Meeting of the American Epilepsy Society; December 2–6, 2016; Houston, TX Schoonjans A-S, Marchau F, Paelinck B, et al. Long-term efficacy and safety of low-dose fenfluramine treatment in Dravet syndrome: follow-up of the original patient cohort. Presented as part of Zogenix scientific exhibit. 70th Annual Meeting of the American Epilepsy Society; December 2–6, 2016; Houston, TX